<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 114 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page113.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=114">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 114 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 114</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=114"><img src="../thumb/114.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Musculo-Skeletal Agents / Autonomic - 4.7.1 / 4.7.2 / 4.7.3 / 4.7.4 / 4.7.5 / 5 / 5.1 / 5.2  2020-04 / 83
       Dosage: Skelet.condits.in pts.with advanc. malign.involv.  Dosage: Adults & childr.over 20 kg bm: 1 µg dly. Childr.und. 20 kg   Dosage: Admin.immed.in case of life-threaten. react., Adults &
       bone: Adults & elderly: Reconstit. 4 mg in 5 ml H 2O then furth.dil.  bm: 0,05 µg/kg dly. Maint. dos: 0,25-1 µg dly.  childr.with bm &gt;45 kg: Use Epipen Auto-injector. Childr.with bm
       in 100 ml NaCl 0,9%/ 5% gluc sol.as IV infus.over 15 mins.every   Contraindications: Hypercalcaem., Vit.D intoxicat., 1st trimest.  &lt;45 kg: Use Epi-Pen Jr Auto-injector. A 0,3 ml dos.is automat. inj.
       3-4 wks. Admin.oral 500 mg calcium supplem.& 400 IU Vit.D dly.  pregn.  IM. Sngl.dos.admin.only. Discard.unused portion.
       Tumour-induc.hypercalcaem: Adults & elderly: Recomm.dos.  Side effects: Hypercalcaem., Ca & Vit.D intoxicat.  Contraindications: Sulphite sensitiv., inj.into buttock.
       (Albumin-correct.ser.calcium &gt; 12,0 mg/dL or 3,0 mmol/L) is 4 mg   Special precautions: Imp.ren.funct., reg.plasma Ca determinat.  Side effects: CNS effs., headache, psychot. states, GI disturbs.,
       dil.in 100 ml NaCl 0,9%/5% gluc.sol.as sngl.IV infus.over 15 mins.   essent., pregn., lactat.  trem.& weakn., cerebr. haemorrh., pulm.oed., dyspn., CV effs., hy-
       Maint.pt.hydrat.prior to & follow.admin.  Drug interactions Barbit.& other anticonvuls. drugs interfere   potens. with dizzin., diffic.micturit., urin.retent., sweat., hypersali-
       Skelet.relat.events in pts.with advanc. malign. involv.bone:   with hepat.convers.  vat., alt.metabol.
       Based on ser.creatin. lev.& clear.determin. Recomm.dos: Baseline   Special precautions: Emerg.ther.which should not substit.any med.
       creatinine clear.(ml/min): &gt;60: 4,0 mg, 50–60: 3,5 mg, 40-49: 3,3 mg,   ROCALTROL, Roche [P/S]  care to be implem.at a later stage, hospital.& appropr.treatm. recomm.
       30-39: 3,0 mg. Meas.ser.creatinine bef. every dos. withhold.if ren.  Calcitriol.  in case of accident. inj., avoid intravasc.inj., hyperthyroid., ischaem.
       funct.deterior.resum. only when creatinine lev.return to within 10%   Indications: Postmenopaus.osteoporos., ren. osteodystrophy, hy-  heart dis., arrhythm., tachycard., hypertens., aneurysm, diab.mellit.,
       of baseline values. See prod.lit.for instruct.for prep. reduc.dos. Liq.  pophosphataem.Vit.D resist.& pseudo Vit.D defic./nutrition.& malab-  clos.angle glauc., antihypertens.ther.
       conc.must be furth.dil.in 100 ml NaCl 0,9%/5% gluc.sol.and admin.  sorpt.rickets, osteomalac., hypoparathyroid., pseudo-hypoparathyroid.  Warnings: Check for brown discolourat.& turbidity every 14 days.
       as IV infus.of no less than 15 min.  (S4) CAPS. M/22.1.4/84.  Drug interactions: Poss.interacts.with MAOI & alpha & ß-blocks.
       Contraindications: Safety in pregn.& lactat. not est., sev.imp.ren.  761249-001: 0,25 µg, 30, R338,49
       funct., safety & effic.in paed. pts.not est., limit.data avail.in sev.hepat.  Dosage: Optim.dly.dos.indiv.accord.to biochem. repons.foll.init.  PHARMA-Q ADRENALINE INJECTION 1 MG/ML, Pharma-Q
       insuff., do not mix. with calcium contain.sols.  dos. Start with low.dos. Adeq.Ca intake necess.for optim.eff.with   Adrenaline tartrate.
       Side effects: Osteonecros.of jaw predomin.in Ca pts., incapacitat.  Ca supplem.poss. necess.  Indications: Where sympathomimet.are reqd.
       bone/joint &/or musc.pain, ren. toxic., flu-like syndr., myalg., arthralg.,   Post-menopaus.osteoporos: Init: 0,25 µg 2x/ day.  (S4) INJ. 30/5.1/0395. 1 mg/ml.
       decr.ser. phosph.lev., GI disturbs., loc./skin reacts., conjunctivit., sev.  Ren.osteodystrophy(dialysis pts): Init.dly.dos: 0,25 µg. Pts.with   895164-019: 10x1 ml, R32,19
       anaem., bld.dyscras., CNS effs., headache, dizzin., paraesthes., trem.,   norm./slightly reduc.ser.Ca: 0,25 µg every other day. Dos.may be incr.  Dosage:
       psych. disords., vis.disturbs., uveit., episclerit., dyspn., cough, incr.  by 0,25 µg/day at 2-4 wks.interv.within.2-4 wks.if satisf.respon.not   Bronch.spasm: Admin.SC. Adults: 0,1-0,5 ml of 1 in 1000 aque-
       sweat., musc.cramps, hypertens., hypotens. poss. lead.to circulat.   observ. Most pts.respon.to 0,5-1.0 µg dly.  ous sol. (100-500 µg). Childr: 0,01 ml/kg bm (10 µg/kg bm) to max.
       collapse esp.with underly. risk fact., bradycard., ren./urin. disords. incl.   Hypoparathyroid., rickets: Recomm.init.dos: 0,25 µg/day in the   tot.dos 0,5 ml (500 µg)
       ac.ren.fail., hypersens.reacts. incl. angioneurot. oed., fev., asthen., pe-  morn. Dos.may be incr.at 2-4 wks.interv.if satisf.respon.not observ.  Ac allergy & anaphylact.shock: Admin SC/pref. IM. Adults:
       riph.oed., chest pain, weight incr., hypophosphataem., hypocalcaem.,   Intermitt. (pulse) ther.2-3x wkly.has been effect. Do not exceed   0,2-0,5 ml as a 1 in 1000 sol. Admin. up to 1 ml & more than 1
       hypernatraem., hypomagnesaem., hyper-/hypokalaem., class.assoc.  max.cumulat.dos.of 12 µg/wk  dos.poss.reqd.
       broncho-constrict. in aspir.sens.asthmat.  Contra-indications: Hypercalcaem., Vit.D intox., lactat.  Cardiovasc.resuscitat: Admin.dil.sol.slow IV. Recomm.dos: 0,5-
       Warnings and special precautions: Ensure adeq.hydrat.prior to   Side-effects: Hypersens.reacts., hypercalcaem. syndr., prurit., rash,   1 ml (0,5-1 mg) dil.10x to 5-10 ml (1 in 10 000 sol). Dos.may be admin.
       admin., avoid overhydrat. in CF risk pts., monit.ser.lev.of Ca/phosph/  urticar., sev.erythem.skin disords., Ca intoxic., weakn., headache,   every 5 mins.dur.prolong.resuscitat.effort.
       Mg & ser creatin. aft.init.ther.& supplem.if necess., caref. monit. of   somnol., GI disords., musc.& bone pain, metall.taste, polyur., poly-  Contraindications: Hypertens., arterioscleros., aneurysms, CV dis.,
       ren.funct.dur.ther., benef.-risk eval.in ren. funct.deteriot., when decid.
       to treat pts with bone metastas. for skelet.relat.event prev.consid.  dips, photophob., rhinorrh., hypertherm., decr.libido, albuminur., high   hyperthyroid., MAOI.
                                                                  Side effects: CNS effs., card.effs., reduc.appet., N&V, weak/cold
                                     cholester., ectop.calcificat., nephrocalcinos., hypertens., dysrhythm.,
       onset of treatm.eff.is 2-3 mnths., fact.incr.potent.for ren. funct. de-
       teriorat.incl.dehydrat./pre-exist.ren. impairm/ multipl.bisphosphonate   rarely psychos., dystrophy, sensory disturbs., fev.with thirst, dehydrat.,   extremit., gangr.follow.infiltrat.of fing./toes, diffic.micturit., urin.re-
       treatm.cycles/ nephrotox. meds & admin.over short.infus.time, dent.   apathy, arrest.growth & UTI,.concurr. hypercalcaem. & hyperphospha-  tent., dyspn., gluc. metabol.disturbs., sweat., hypersalivat., headache.
       exam.bef.init.ther.in pts.with concom.risk fact., avoid invas.dent.pro-  taem., soft tiss. calcificat.  Special precautions: Ang.pain precipit.in ang pect.pts., diab.mel-
       ced.dur.ther.as jaw osteonecros. poss.exacerbat., teratogen.in rats.,   Special precautions: Ser.Ca.x phosph.prod. (Ca x P) not allow.  lit., clos.ang.glauc., halog. anaesthet.
                                             2 2
       concom. potent.nephrotox.drugs, low.dos.recomm. in bone metast.  to exceed 5,6 mmol /l , withold Vit.D & derivat.dur.treatm., switch.  Drug interactions: Incr.arrhythm.risk if giv.with card. glycosid./
       Drug interactions: Incr.ren.dysfunct.risk in multip.myeloma pts.  from ergocalciferol to calcitriol, avoid dehydrat.in pts.with norm.ren.   quinid./TCA’s, MAOI’s.
       with thalidomide, addit. eff.with aminoglycos.low.ser.Ca lev.& poss.   funct., maint.adeq.fluid intake, strict.adher.to diet. Ca supplemen-
       hypomagnesaem.                tat., digital.treatm., adjust phosph. bind.agents dos.in accord.with
                                     ser.phosph conc., Vit D resist.rickets pts.to cont.monit.oral phosph.
                                     ther., vit.D teratogen.in animals, use only in pregn. for hypoparathy- 5.2  Sympatholytics
       4.7.2   Selective oestrogen    roid.if therapeut.benef.clear. outweighs poss.S/E, tot.dly. Ca intake      (See also 7.2, 7.3, 7.4)
                                     from food & drugs should average 800 mg not to exceed. 1000 mg.,
                                     low dos./discont.for hypercalaem., monit. ser.Ca lev.at least 2x wkly.
              receptor modulators    dur.stabilisat. phase thereaft.mnthly. stop treatm.immed.if ser. Ca   ESMOCARD, Equity [N/P/S in C in certain sports]
                                                                  Esmolol HCl.
                                     or ser.creatin.lev.exceed accept.norm.limit for age, 24 hr.urine Ca   Indications: Supraventric.tachycard.incl.rapid contr. of ventric.rate
       EVISTA, Eli Lilly             init.at 4 wks./3 & 6 mnths & then 6 mnthly., dur.hypercalcaem.ser.  in atrial fibrillat./atrial flutter in perioperative/postop./other emergent
       Raloxifene HCl                Ca & phosph lev.determ.dly., once normocalcaem.attain.aft. hyper-  circumst. where short-term contr.of ventric.rate with short act.agent
       Indications: Osteoporos.treatm.& prevent.in post-menopaus.wom-  calcaem.cont.treatm.at dly dos.of 0,25 µg low. than that prev.used,   desirable; noncompensat.sinus tachycard. where rapid heart rate
       en, risk reduct. for developm.of invas.breast Ca in postmenopaus.   guard against hypercalciur., monit.indices of respon, malabsorpt. in   req.specif. intervent.; intra-operative/postop.tachycard.& hypertens.
       women with osteoporos.        hypoparathyroid.poss., immobil.pts., ren.fail.  (S3) SOL.FOR INFUS. 45/5.2/0806.100 mg/10 ml
       (S3) TABS. 32/34/0422.        Drug interactions: Incr.risk of hypercalcaem. with thiazide diuret.,   3000539-001: 10 mg/ml, 5 vials, R1 131,03
       847461-009: 60 mg, 28, R670,37  funct.antagon.betw.vit.D analog.& corticoster, hypermagnesaem.  Dosage: Admin by IV infus; Admin for &gt;24 hours not eval. & caut.
       Dosage: 1 tab.dly.            with Mg contain.drugs, effs.phosph.transport in intestine, kidn.&   advis. Not compatible with sod. bicarbon (5 %) inj.
       Contraindications: Act./past hist.of ven. thromboembol. events   bone, enzyme induc.(eg.phenytoin/ phenobarb.) may incr.metabol.  Supraventricular tachycardia: Dos.to be individ. by titrat.in
       incl.DVT/ pulm. embol./ retin. vein thrombos., liv.cirrh., pregn.& lactat.  reduc.serum conc., cholestram.reduc.intestin.absorpt.of fat.sol.vits.  which each step consists of a load.dos.follow.by a maint.dos: Load.
       Side effects: Hot flush., ven.thromboembol. events incl.retin.  infus.of 500 µg/kg/min over 1 min.then maint.infus.of 50 µg/kg/min
       vein thromb., periph. oed., leg.cramps, GI sympt., rash, decr.platel.  over 4 min; if respon.inadeq.repeat load.infus.& incr.maint.infus.to
       counts, ALT/AST incr.                                      100 µg/kg/min. Ref.to prod.lit.for full titrat.guideline. Effect.maint.
       Warnings and special precautions: Ca supplem. in women with  4.7.5   Dual action bone agents  dos: 50-200 µg/kg/min. although dos.as low as 25  µg/kg/min and
       intake less than 800  mg/day, not for vasomot.sympt.relief, not to be      No products listed  as high as 300 µg/kg/min.(not recomm.as little addit.eff.prov.& adv.
       used in endometr.Ca, incr.ovarian tumour risk in experim. rats, uter.  eff.incr.) have been used.
       bleed.dur.ther.to be investig., safety in breast Ca not est., not recomm.  Not stud.intra-operat.& due to titrat.time reqd.poss.not optim.for
       in hepat. insuff., not for lact.intol.pts., concom. cholestyramine, monit. 5  AUTONOMIC  intra-operat.use.
       prothromb.time with warfar., concom.syst.oestrog.not recomm., incr.   Aft.pts.achieve adeq.control of heart rate & stable clinic.status transit.
       congenit. defect risk in foet.if admin.dur pregn., not to be used in   to alternat.drugs (incl.anti-arrhythm./Ca antagon.) may be accomplish.
       women of childbear.potent., consid. benef/risk in postmenopaus.  5.1  Sympathomimetics  Refer to prod.lit for transit.guideline.
       women with stroke hist./other signif.stroke risk fact., discont. treatm.   Intra- & post-operat. tachycard. &/ hypertens: Two dos.options as
       as soon as poss. in cases of prolong. immobilisat. & restart only when       (See also 7.6, 10.1.2)  slow titrat.of dos.to a therapeut. eff.not always advis.: Immed.control
       init.condit. resolv. & pt.full.mobile, oral oestrog.induc. hypertriglyceri-  dur. anaesthes: For intra-operat.treatm.of tachycard. &/ hypertens:
       daem. hist.in which case monit.ser. triglycerid. dur.ther., reduc.incid.  ADRENALINE FRESENIUS, Fresenius Kabi [N/P/S in C]  bolus dos.of 80 mg (approx.1 mg/kg) over 30 secs.follow.by 150 µg/
       of non-traumat. vertebr. fract.in postmenopaus.women, not applic.   Adrenaline tartrate  kg/ min (0,15 mg/kg/min) infus.if reqd. Adjust. infus.rate as need up
       to oestrog. recept.negat.Ca & Ca of unknown oestrog. recept.status.  Indications: Where sympathomimet.are reqd.  to 300 µg/kg/min (0,3 mg/kg/min). Grad.control: For post-operat
       Drug interactions: Cholestyramine reduc. absorpt. & enterohepat.  (S4) INJ, C923. 1 mg/ml.  tachycard. & hypertens: Dos.sched.is the same as for SVT above.
       cycling, decr. prothromb. time with warfar.  701211-008: 10x1 ml, R48,78  Contraindications: Sinus bradycard.(heart rate &lt; 45 bpm), heart
                                     Dosage: Admin.by SC/IM inj.  block &gt; than 1st degr, cardiogen. shock, heart fail., pheochromocyt.,
                                     Adults: 0,2-0,5 ml. Childr: 0,1-0,3 ml.  asthma/ bronchoconstrict/chron.resp.dis.hist.incl.bronchit., late
       4.7.3  Calcitonin             Contraindications: Hypertens., arterioscleros., coron.dis., hyper-  phase periph. vasc.dis./ Raynaud’s phenomen.
                                     thyroid., MAOI, diab.mellit., glauc., phaeochromocyt., Parkinson’s,
                                                                  Side effects: Freq: Hypotens., dizzin. Less freq: Bradycard., chest
              No products listed     psychoneuros.                pain, reduc.periph.circulat., flush./ pale skin, faint., confus., head-
                                     Side effects: Hypersens.reacts., gangrene poss. follow.infiltrat.of
                                     finger/toes, CNS effs., hypertens., tachycard., card.dysrhythm., diffic.   ache, fev., anx./ nervousn., bronchosp., wheez., dyspn., N&V, ano-
                                                                  rex., skelet.musc.weakn., hypersens.reacts., redn., pain & swell.at
       4.7.4   Minerals and vitamin D  micturit., urin.retent., sweat., hyposalivat., headache.  inj.site. Freq.unknown: Periph. ischaem., pulm.oed., heart block,
                                     EPIPEN, Mylan [N/P/S in C]   CHF, asymptomat. hypotens., symptomat.diaphores., somnol., fatig.,
       ONE-ALPHA, (AI Crit.Care) AI Ltd [P/S]  Adrenaline         paraesthes., gen.tonic-clonic seiz., agitat., speech disord., depress.
       Alfacalcidol.                 Indications: Adjunct.in sev.anaphylact./life threaten. reacts.  & abnorm.think., vivid dreams & nightmar., dyspeps., constip., dry
       Indications: Ren.bone dis., hypoparathyroid., second.hyperparathy-  (S4) AUTO-INJECTOR, [N/P/S in C] 27/5.1/0063  mouth, abdom.discomf., taste pervers., eryth., skin discolour., urin.
       roid., hypophosphataem. Vit. D-resist.rickets & osteomalac., pseudo   797642-005: 0,3 mg/0,3 ml, Sngl.dos.pre-fill. automat. inj.dev.,   retent., abnorm.vision, dry eye, asthen., burn.at infus.site, thrombo-
       defic.(D-dep) rickets., nutrit.& malabsorpt.rickets & osteomalac.  R1 027,92  phlebit., loc. skin necros., oed.
       (S4) CAPS, [P/S] M/22.1.4/261, 262.  (S4) JR AUTO-INJECTOR, [N/P/S in C] 38/5.1/0278  Warnings and special precautions: Not intend. for use in chron.
       750654-007: 0,25 µg, 30, R277,70  707128-001: 0,15 mg/0,3 ml, Sngl.dos.pre-fill. automat.inj.dev.,   settings where transf.to anoth. agent anticipat., not recomm.for pre-
       750662-018: 1 µg, 30, R862,72  R1 027,92                   vent.of intra-operative/postop.tachycard.& hypertens., safety & effic.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page113.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page109.html">109</a>&nbsp;&nbsp;&nbsp;<a href="page110.html">110</a>&nbsp;&nbsp;&nbsp;<a href="page111.html">111</a>&nbsp;&nbsp;&nbsp;<a href="page112.html">112</a>&nbsp;&nbsp;&nbsp;<a href="page113.html">113</a>&nbsp;&nbsp;&nbsp;<a href="page114.html">114</a>&nbsp;&nbsp;&nbsp;<a href="page115.html">115</a>&nbsp;&nbsp;&nbsp;<a href="page116.html">116</a>&nbsp;&nbsp;&nbsp;<a href="page117.html">117</a>&nbsp;&nbsp;&nbsp;<a href="page118.html">118</a>&nbsp;&nbsp;&nbsp;<a href="page119.html">119</a>
             </td>
             <td width="35%"><a href="page115.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page115.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
